Michael Mrochen

About Michael Mrochen

“My work has focused on advancing ophthalmic innovation through a series of execution milestones – moving concepts from development into regulated pathways, from early adoption into commercial deployment, and from isolated clinical excellence into scalable systems capable of broad impact.

“Allotex transitioned from a development-focused organization into a commercial-stage company outside the United States, with active clinical use across multiple European markets. In parallel, the company formally entered the US regulatory pathway through approval of an FDA Investigational Device Exemption (IDE), establishing the framework for US clinical trials. These milestones positioned tissue-based corneal lenticule implantation as a defined new refractive category, rather than an experimental approach.

“In addition, ray-tracing–based ablation principles that I previously developed with my IROC team reached full-scale clinical deployment through Alcon’s WaveLight Plus platform. Over the past 12-18 months, WaveLight Plus achieved FDA approval and broad international commercial rollout, marking the first large-scale implementation of full-eye optical modeling as a standard refractive workflow.

“As a Board member of SCHWIND eye-tech-solutions, my involvement during this period coincided with a major geographic expansion milestone: the ATOS femtosecond laser platform progressed through regulatory clearance and commercial expansion in China, one of the world’s most demanding refractive markets. At the clinical delivery level, my board responsibilities at Pallas Kliniken aligned with a phase of operational consolidation and strategic modernization. The group implemented targeted initiatives to address future challenges related to digitalization, reimbursement pressures, and the sustained delivery of high-quality medical services.

“I also supported Swiss Vision Group at a strategic level during a formative start-up phase. My involvement contributed to sharpening the clinic’s clinical focus toward becoming the first Tissue Addition–focused eye clinic, while strengthening its positioning within international professional contexts.

“These milestones reflect a consistent focus on crossing execution thresholds: advancing new refractive concepts into regulated clinical use, embedding advanced optical planning at global scale, expanding refractive platforms into new markets, and building clinical systems capable of sustaining innovation in everyday ophthalmic practice.”